Prostate cancer (PCa) is still the leading cause of death among males worldwide and an enormous burden for the healthcare systems. Therefore, huge efforts were made to understand the molecular basis of PCa and to reveal biomarkers for predicting the clinical course of the disease. The advent of new and highly efficient sequencing technologies (e.g. next-generation sequencing \[NGS\]) allowed the analysis of whole tumor cell genomes and brought deep insights into molecular alterations of these cells. Using these tools, the search for molecular biomarkers will progress rapidly.

In PCa, NGS studies revealed the speckle-type POZ protein (SPOP) as one of the most frequently mutated genes reported so far recently. The average rate of SPOP mutation was about 10% in primary and metastatic tumors, and these mutations were suggested to be an early event in prostate carcinogenesis.[@ref1] Interestingly, wild-type SPOP degrades full-length androgen receptor (AR) and possesses functions of a tumor-suppressor. Mutated SPOP is no longer capable of this AR degradation and was supposed to be involved in the resistance of an anti-androgen-therapy of PCa.[@ref2]

Most of these data on SPOP mutations came from studies on Caucasian patient cohorts only. As the published studies hypothesize a general role of SPOP alterations in PCa analysis of patients from diverse ethnicity is urgently needed. Buckles *et al*.[@ref3] present a comprehensive study of SPOP mutation analysis in African American PCa patients (*n* = 49). Although, only a relatively small number of patients analyzed SPOP mutations were found in 10% of the cases. Most recently, a very similar study was published by Khani *et al*.[@ref4] Herein, a mutation frequency of only 4.5% (*n* = 4/88) was reported with an overlapping mutation spectrum between both studies. As Khani *et al*.[@ref4] isolated tumor DNA from tissue cores detection of SPOP mutations might have been hampered by the presence of a lot of nonneoplastic cells within the cores. As Buckles *et al*.[@ref3] used macro dissection before DNA isolation a high purity of the tumor cells could be expected. Nevertheless, Khani *et al*.[@ref4] found no significant difference in the SPOP mutation frequency between Caucasian and African American PCa patients. Both reports underline the general importance of SPOP mutation in PCa. In addition, Buckles *et al*.[@ref3] also found a decreased SPOP expression on mRNA level in mutated tumors. Unfortunately, SPOP expression analysis on protein level was not done on the tumor tissue. Kim *et al*.[@ref5] showed that more than 35% (*n* = 22/60) of the analyzed PCa cases lost SPOP expression using immunohistochemistry, but only two cases with SPOP mutation were analyzed in parallel for mutation and expression. It will be of great interest if somatic mutations are the cause of the expression loss or if other mechanisms (e.g. epigenetic, posttranscriptional or posttranslational modification) are involved in SPOP protein loss.

Remarkably, Buckles *et al*.[@ref3] could also report a significant correlation between the presence of SPOP mutation and aggressive PCa. As a correlation between SPOP mutations and histopathological characteristics of the tumors was not found to date, validation of this clinical important impact of SPOP mutation on PCa is urgently needed.

Taken together, the reported studies on the role of SPOP alterations in PCa provide a promising new, and presumably large tesserae of the overall picture of PCa that hopefully improve management of this disease in the future.
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